Evidence mapPaperPMID 42588554Full record

ArticleMolecules (Basel, Switzerland)2026

Kimberlyn Feguro, Norsyahida Mohd Fauzi, Khairana Husain, Sarmila Hanim Mustafa, Malina Jasamai

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kimberlyn FeguroCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.ORCID 0009-0007-0668-5847
Norsyahida Mohd FauziCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.ORCID 0000-0001-8947-2810
Khairana HusainCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.ORCID 0000-0002-0333-0334
Sarmila Hanim MustafaCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Malina JasamaiCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.ORCID 0000-0003-1575-369X

Funding

Ministry of Higher Education FRGS/1/2019/SKK06/UKM/02/1
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterised by excessive lipid accumulation in hepatocytes and often accompanied by dyslipidaemia.

Indexed as

AsteraceaeCholesterolFatty LiverGene Expression RegulationHepatocytesOleic AcidPlant ExtractsAnimalsHumansHydroxymethylglutaryl CoA ReductasesLipid MetabolismProprotein Convertase 9Receptors, LDLSterol Regulatory Element Binding Protein 2StigmasterolCholesterolHydroxymethylglutaryl CoA ReductasesOleic AcidPlant ExtractsProprotein Convertase 9Receptors, LDLSterol Regulatory Element Binding Protein 2StigmasterolGynura procumbensMASLDPCSK9SREBP2stigmasterol

Identifiers

PMID42588554
PMCPMC13467583

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.